Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists-Reference-Cited by-同舟云学术

Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists

Published:2022-05-04 Issue:3 Volume:56 Page:169-175
ISSN:2168-1805
Container-title:Scandinavian Journal of Urology
language:en
Short-container-title:Scandinavian Journal of Urology

Author:

Bonde Tiago M.¹,Westerberg Marcus²,Aly Markus³⁴,Eklund Martin⁵,Adolfsson Jan⁶,Bill-Axelson Anna⁷,Garmo Hans⁷^ORCID,Stattin Pär⁷,Robinson David¹

Affiliation:

1. Department of Urology, Ryhov Hospital, Jönköping, Sweden

2. Department of Mathematics, Uppsala University, Uppsala, Sweden

3. Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

4. Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden

5. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

6. Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

7. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Funder

Swedish Cancer Society

the Swedish Research Council

the Clinical Cancer Research Foundation in Jönköping, Sweden

FUTURUM - Academy for Healthcare, Jönköping County, Sweden

Publisher

Medical Journals Sweden AB

Subject

Urology,Nephrology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21681805.2022.2070275

Reference27 articles.

1. Androgen deprivation therapy: past, present and future

2. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?

3. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer

4. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

5. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer;International Urology and Nephrology;2023-07-31